Drug, bio-affecting and body treating compositions inventions 05/07

20070122341 - Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques: wherein R1-R5 are independently selected from hydrogen, C1-C4 alkyl and F (at least one of them is F) and each R6-R10 are independently selected from hydrogen, C1-C4 alkyl, OH, OCH3, NH2, NHCH3 and N(CH3)2 (at least one of them is OH, OCH3, NH2, NHCH3 or N(CH3)2) are disclosed. Benzylideneaniline derivatives... Agent: Heslin Rothenberg Farley & Mesiti PC

20070122342 - Ethylenedicysteine (ec)-drug conjugates compositions and methods for tissue specific disease imaging: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a... Agent: Fulbright & Jaworski L.L.P.

20070122340 - Necrosis avid tracer agent: The present invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging.... Agent: Clark & Elbing LLP

20070122343 - Non-invasive assay for the assessment of functioning and/or structure of the gut: The present invention relates to a diagnostic method for assessing the functioning and/or structural integrity of the gut in animal subjects. The method of the present invention is predicated on assessing the absorption and/or metabolism of one or more test sugars or functional equivalents such as phosphorylated sugars, oligopeptides or... Agent: The Mccallum Law Firm, P. C.

20070122346 - Conjugated macromolecules: A method of conjugating a carboxylate-containing molecule to an amine-containing macromolecule to form a substituted macromolecule is provided. The method includes (a) forming a first solution by dissolving a substance comprising at least one macromolecule having free amine groups in an aqueous basic solution; (b) forming a second solution by... Agent: General Electric Company Global Research

20070122347 - Method and system for automated supervised data analysis: The invention relates to a method for automatically analyzing data and constructing data classification models based on the data. In an embodiment of the method, the method includes selecting a best combination of methods from a plurality of classification, predictor selection, and data preparatory methods; and determining a best model... Agent: Miles & Stockbridge PC

20070122344 - Intraoperative determination of nerve location: The invention provides methods for intraoperatively determining the location of nerves by use of fluorescent dyes. The methods are particularly useful for locating the cavernous nerves innervating the penis.... Agent: Townsend And Townsend And Crew, LLP

20070122345 - Intraoperative determination of nerve location: The invention provides methods for intraoperatively determining the location of nerves by use of fluorescent dyes. The methods are particularly useful for locating the cavernous nerves innervating the penis.... Agent: Townsend And Townsend And Crew, LLP

20070122348 - Opioid agonist/antagonist combinations: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective... Agent: Davidson, Davidson & Kappel, LLC

20070122351 - Inhalation drug combinations: A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteriod, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteriod is... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070122352 - Inhalation drug combinations: A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteroid, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteroid is... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070122349 - Measuring particle size distribution in pharmaceutical aerosols: Disclosed herein are methods for measuring the particle size distribution of a pharmaceutical aerosol, including methods utilizing laser diffraction.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070122350 - Safe and effective methods of administering therapeutic agents: In one embodiment, the invention relates to a kit for administering a lipid-based platinum compound formulation via inhalation comprising: an inhalation device comprising a lipid-based platinum compound formulation, a demistifier tent of sufficient size to at least cover a patient's head and the inhalation device, and instructions for use thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070122353 - Drug condensation aerosols and kits: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a... Agent: Swanson & Bratschun, L.l.c

20070122354 - Storage stable powder compositions of interleukin-4 receptor: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.... Agent: Nektar Therapeutics

20070122355 - Rapidly absorbing oral formulations of pde 5 inhibitors: e

20070122356 - Glass compositions as an antimicrobial additive for dental materials: The invention relates to a use of glass compositions having an antimicrobial and/or disinfectant effect in materials used for restoring teeth, excluding implants.... Agent: Baker & Daniels LLP 111 E. Wayne Street

20070122357 - Dentifrice composition: Dentifrice compositions which provide chemical cleaning of the oral surfaces with a combination of surfactant, chelant, and pH; further this dentifrice composition can minimize the use of abrasives to provide a gentle cleaning of the oral surfaces.... Agent: The Procter & Gamble Company Intellectual Property Division

20070122359 - Dentifrice composition comprising binder system comprising hydrophilic clay material: A dentifrice composition which provides a viscosity of from about 10,000 Pas to about 450,000 Pas comprising; (a) a binder system comprising a hydrophilic clay material, a modified cellulose polymer, a carboxyvinyl polymer and a natural gum derived anionic polymer, (b) an effective amount of an oral care active, and... Agent: The Procter & Gamble Company Intellectual Property Division

20070122358 - Dentifrice composition free of abrasive material: A dentifrice composition comprising, (a) a hydrophilic clay material, (b) a phytic acid compound, (c) an effective amount of an oral care active, and (d) a polar solvent carrier; wherein the composition is substantially free of abrasive material.... Agent: The Procter & Gamble Company Intellectual Property Division

20070122362 - Hydrogel sheets and shapes for oral care: A hydrogel for use in oral care. The hydrogel is ion beam cross-linked, the hydrogel is adapted to be disposed in the oral cavity and may be adapted to provide a denture fixative or may be loaded with a whitening agent for use in whitening one or more teeth and... Agent: Berenbaum, Weinshienk & Eason, P.c

20070122360 - Nonaqueous gel composition for tooth whitening and tooth whitening set: A nonaqueous gel composition for tooth whitening, comprising: (A) tooth whitening ingredient having a relative permittivity of 17.0 to 43.0 (at 25° C.) and a vapor pressure of 0 to 7000 kPa (at 25° C.), (B) substance that is soluble in the tooth whitening ingredient and is precipitated by an... Agent: Birch Stewart Kolasch & Birch

20070122361 - Tooth colorant and whitener, method of manufacture, and method of use thereof: A polymerizable tooth colorant composition, comprising: a polymerizable resin composition; an additive composition comprising a colorant, a whitener, or both; and a curing system. The composition allows easy coloring and/or whitening of teeth.... Agent: Cantor Colburn, LLP

20070122363 - Corporeal delivery of carotenoids: A method for delivery of a phytochemical supplement to a corporeal body. The method of delivery comprises providing a phytochemical supplement in an orally acceptable composition and applying the orally acceptable composition including the phytochemical supplement in contact with a feature of the oral cavity of a corporeal body. An... Agent: Berenbaum, Weinshienk & Eason, P.c

20070122364 - Self-tanning facial product having anti-wrinkle/anti-aging properties: A sunless facial self-tanning composition having anti-wrinkle/anti-aging properties. The composition contains safe effective amounts of sunless or self-tanning agents and peptides having anti-wrinkle/anti-aging properties. A method for preparing such composition is disclosed.... Agent: Dunlap, Codding & Rogers P.C.

20070122365 - Skin-tightening preparations containing gliadin: The present invention is concerned with preparations for application to human skin including a cream or lotion base together with a quantity of a skin-tightening agent consisting essentially of gliadin. Products such as creams, lotions, facial masks and sunscreens can be prepared which exhibit desirable skin-tightening or anti-wrinkle effects.... Agent: Hovey Williams LLP

20070122366 - Preparations for the care nails that contain terbinafine hydrochloride: There are provided topical preparations for the care of fingernails and toenails. The preparation is in the form of a varnish solution that contains Terbinafine Hydrochloride as an active ingredient and a vehicle formulated with all or some of the following components: ethyl alcohol, poly (methyl vinyl ether alt maleic... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070122367 - Resorcinol derivatives: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.... Agent: Warner-lambert Company

20070122368 - Preparation, in particular cosmetic preparation, and the production and use thereof: A preparation, in particular a cosmetic preparation, preferably in liquid or pasty form, for use on keratinic materials, in particular for decorating, coloring, improving the appearance of and caring for the skin and the skin appendages. The preparation is water-free and contains at least one wax with a dropping point... Agent: Bachman & Lapointe, P.C.

20070122369 - Cosmetic hair composition: The hair cosmetic composition contains a solvent-containing silicone emulsion (A) which is prepared by emulsifying a mixture of high-molecular-weight polyorganosiloxane (a) obtained by emulsion polymerization and a volatile solvent (b), a surfactant (B) and water (C). The component solvent-containing silicone emulsion (A) is contained at a ratio of 0.1-10 wt... Agent: Foley And Lardner LLP Suite 500

20070122372 - Amino-functional silicone waxes: The present invention relates to silicone waxes having plural tertiary or quaternary amino groups, their preparation and their use as softeners in the textile industry. These waxes can be processed into stable aqueous dispersions and lead to products having a pleasant, soft hand.... Agent: Clariant Corporation Intellectual Property Department

20070122370 - Compositions comprising oligoglycosides: Compositions containing an alkyl or alkenyl oligoglycoside and mixtures thereof, and a hydroxycarboxylic acid partial ester of an alkoxylated alcohol are provided.... Agent: Cognis Corporation Patent Department

20070122371 - Cleansing composition: There is provided a cleansing composition which has creamy foaming and excellent cleansing power, provides no stretched feeling of skin after rinsing and a refreshed feeling of skin, is excellent in storage stability and exhibits no reduction in physical properties, formation of precipitates and yellowing during a long-term storage period... Agent: Staas & Halsey LLP

20070122373 - Air freshener: Air freshener products and methods for freshening air are disclosed. In some embodiments, the air freshening product may include a container for storing an air freshening composition that may contain a perfume composition or may contain a perfume composition in conjunction with a malodor counteractant. The container may contain a... Agent: The Procter & Gamble Company Intellectual Property Division

20070122374 - Waterless urinal formulations: The present invention relates to A composition for use in urinals, comprising: (a) one or more aliphatic alcohols, the aliphatic alcohols comprising 11 carbon atoms or less; (b) one or more esters selected from molecules of formula R1—C(O)—O—R2 and triglycerides of formula CH2COOR6—CHCOOR7—CH2—COOR8, R1 comprising 6 to 24 carbon atoms,... Agent: Sonnenschein Nath & Rosenthal LLP

20070122375 - Bile acid sequestrant and process for preparation thereof: The present invention describes a copolymer comprising multiple unsaturations, which are obtained by polymerization of dimethyl β-cyclodextrin inclusion complex of monomer containing multiple vinyl unsaturation and amine functional monomer. These water soluble copolymers containing unsaturation sites, crosslinked in the presence of bile acid template. This novel sequential polymerization and crosslinked... Agent: Ladas & Parry

20070122376 - Pheromones and method of preventing infestation of contarinia nasturtii: The present invention relates to pheromone mixture comprising 2,9 diacetoxyundecane, 2,10-diacetoxyundecane and 2-acetoxyundecane, as a racemate or, biologically active stereoisomers thereof, as well as a method for monitoring and/or mating disruption of swede midge, Contarinia nasturtii, in Brassica vegetables, in particular Brussels sprouts, cauliflower and broccoli.... Agent: Gauthier & Connors LLP

20070122380 - Chimeric cytokine of il-7 and beta-chain of hgf and methods of use: The present invention relates to a single-chain or chimeric polypeptide comprising a cytokine and a growth factor linked by at least one amino acid residue, and wherein the chimeric polypeptide enhances the proliferation and/or differentiation of hematopoietic precursor cells. In particular the invention relates to, a chimeric polypeptide comprising the... Agent: Mccarter & English LLP Cityplace I

20070122379 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition... Agent: Townsend And Townsend And Crew, LLP

20070122377 - Compositions and methods of treatment: A method of inducing tolerance to a therapeutic cell in a patient who is to be administered subsequently a therapeutic amount of the said therapeutic cell or a precursor thereof, the method comprising administering to the patient (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell,... Agent: Nixon Peabody LLP - Patent Group

20070122381 - Method for regulating neuron development and maintenance: The present invention relates to a method for regulating neuron development/maintenance and/or regeneration in a nervous system of a mammal and to pharmaceutical compositions comprising leukaemia inhibitory factor useful for same.... Agent: Scully Scott Murphy & Presser, PC

20070122378 - Methods and compositions for the treatment of persistent infections: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070122383 - Interleukin-10 compositions for the treatment of adenocarcinomas: The present invention is directed to methods for the treatment of adenocarcinomas that are characterized by the overexpression of a particular oncogene, Pim-1. The procedure involves administering a therapeutically effective amount of interleukin-10 that has been coupled to a carrier that increases its circulating plasma half-life.... Agent: Law Office Of Michael A. Sanzo, LLC

20070122382 - Methods of treating cancer using il-21 and monoclonal antibody therapy: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with... Agent: Zymogenetics, Inc. Intellectual Property Department

20070122384 - Method for treating inflammatory bowel disease: A method for treating inflammatory bowel disease by administering interferon beta in conjunction with factor XIII to a mammal afflicted with the disease. The IBD may either be ulcerative colitis or Crohn's disease. The factor XIII used may be recombinant or nonrecombinant. The interferon beta used can be naturally occurring... Agent: Novo Nordisk, Inc. Patent Department

20070122385 - Replication competent viruses capable of silencing virus inhibitory factor expression: Described is a replication-competent virus capable of replication and having lytic capacity in target cells. The virus comprises in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the target cells, operably linked to one or more... Agent: Trask Britt

20070122394 - Compositions and methods for liver growth and liver protection: The present invention provides pharmaceutical compositions and methods for liver proliferation and protection. Specifically useful are VEGFR modulating agents capable of promoting liver growth. Disclosed compositions and methods may be useful for promoting proliferation or treating pathological conditions in other organs of significant biological functions.... Agent: Genentech, Inc.

20070122391 - Compositions and methods for non-targeted activation of endogenous genes: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment... Agent: Lahive & Cockfield, LLP

20070122395 - Genetic and pharmacological regulation of antidepressant-sensitive biogenic amine transporters through pkg/p38 map kinase: The invention relates to the observation that the p38 mitogen-activated protein kinase pathway is an important regulator of biogenic amine transporter (BAT) function. By using modulator of p38 MAPK, one can alter BAT function in a specific manner. This recognition of the pathway and its interaction with the serotonin transporter... Agent: Fulbright & Jaworski L.L.P.

20070122393 - Immunophenotype and immunogenicity of human adipose derived cells: The present invention encompasses methods and compositions for generating an isolated adipose tissue-derived stromal cell exhibiting a low level of immunogenicity. The present invention encompasses methods and compositions for reducing an immune response associated with transplantation by administering the recipient with an amount of adipose tissue-derived stromal cells effective to... Agent: Kathryn Doyle, Ph.d., J.d. Drinker Biddle & Reath

20070122396 - Morphogenic proteins and stimulatory factors in gene therapy: Gene therapy methods for tissue formation, repair and regeneration using nucleic acids encoding morphogenic proteins and morphogenic protein stimulatory factors (MPSFs) are provided.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070122392 - Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel: Embryonic stem cells are propagated in a hyaluronic acid.... Agent: Choate, Hall & Stewart LLP

20070122398 - Encapsulated hydrophilic compounds: The present invention relates to capsules for encapsulating functional agents, such as flavors, fragrances, pharmaceuticals, vitamins, etc. The capsules are suitable for the encapsulation of hydrophobic as well as hydrophilic substances. The capsules include a micro-organism, a matrix component and the encapsulatable material, wherein the latter comprises the functional agent... Agent: Winston & Strawn LLP Patent Department

20070122397 - Probiotic storage and delivery: Probiotic microorganisms are micro encapsulated by dispersing the probiotic microorganism in an aqueous suspension of a film forming protein and a carbohydrate; in an oil in water emulsion of a film forming protein and a carbohydrate and a fat; or in an oil which is subsequently dispersed in a film... Agent: Foley And Lardner LLP Suite 500

20070122390 - Graft with increased resistance to enzymatic degradation: Described are devices, methods, and systems for grafting tissues or organs that are exposed to bacterial or mammalian enzymes that degrade collagenous materials. Illustrative medical grafts are processed by contacting a collagenous extracellular matrix (ECM) material with a mono-carboxylic acid having from four to about twelve carbon atoms, or mixtures... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070122387 - Hair grafts derived from plucked hair: The present invention is a hair graft derived from a plucked hair comprising a plucked hair having adhered epidermal stem cells and associated follicular dermal cells. The present invention also includes methods of making a hair graft, methods of implanting a hair graft and methods of identifying inductive follicular dermal... Agent: Michael Best & Friedrich, LLP

20070122386 - Preparation method of a hair dermal papilla cell preparation, composition and method for regenerating hair follicles, and animal having regenerated hair follicles: The present invention provides a method for preparing a hair dermal papilla cell preparation comprising preparing a cell suspension by removing epidermal tissue from skin tissue and subjecting the resulting dermal tissue fraction to collagenase treatment, and cyropreserving the cell suspension to kill the follicular epidermal cells. The present invention... Agent: Snider & Associates

20070122389 - Stage specific follicle maturation systems: A three-dimensional matrix system is described herein. The system is used to surround developing tissue and support continued interaction between, for example, an oocyte and a supporting cellular structure. Oocytes grown to maturity can then be retrieved from the matrix for subsequent research use and/or fertilization. The systems and methods... Agent: Todd S. Parkhurst Holland & Knight LLP

20070122388 - Tissue graft compositions and methods for producing same: A tissue graft composition is described herein that includes a segment of small intestinal submucosa having at least one nanoparticle incorporated therein such that the permeability of the segment of small intestinal submucosa is altered, thereby providing the segment of small intestinal submucosa with a more substantially uniform structure for... Agent: Dunlap, Codding & Rogers P.C.

20070122399 - Composition and method for facilitating bone healing: The present invention provides a nutritional composition effective in facilitating bone healing in human, comprising lysine, proline, ascorbic acid, copper, vitamin B6. The nutritional composition contains 27-34% wt lysine, 14-16% wt proline, and 42-47% wt ascorbic acid. The nutritional composition further comprises vitamin A, vitamin D3, vitamin E, vitamin B1,... Agent: Kenyon & Kenyon LLP

20070122400 - Composition having liver function protecting effect: The present invention provides a highly safe composition which is effective for protecting liver functions and preventing liver dysfunctions in the case where liver dysfunctions rise by various causes. The present inventors found that oxidized coenzyme Q is effective for protecting liver functions in the absence of selenium and that... Agent: Sughrue Mion, PLLC

20070122401 - Methods and compositions for modulating telomerase reverse transcriptase (tert) expression: Nucleic acid compositions comprising an Ikaros or WT1 repressor binding site that act to repress transcription of the telomerase reverse transcriptase (TERT) coding sequence, as well as vectors and constructs including the same, are provided. Also provided are methods of modulating, e.g., inhibiting, the TERT transcription repressing activity of the... Agent: Bozicevic, Field & Francis LLP

20070122402 - Immunoglobulin preparations having increased stability: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070122403 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant... Agent: Jones Day

20070122404 - Humanized immunoglobulin reactive with alpha4beta7 integrin: The present invention relates to a humanized immunoglobulin that has binding specificity for α4β7 integrin and comprises the complementarity determining regions (CDRs) of mouse Act-1 antibody, and to the humanized light chain of the humanized immunoglobulin. The present invention further relates to a humanized immunoglobulin light chain. The invention also... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070122405 - Human g-protein chemokine receptor (ccr5) hdgnr10: The present invention relates to a human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070122409 - Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor antagonist.... Agent: Catalyst Law Group, Apc

20070122408 - Fc labeling for immunostaining and immunotargeting: The present invention discloses methods of labeling Fc portions of antibodies, or fusion proteins incorporating Fc portions of antibodies, so that they can be used in immunostaining or immunolabeling procedures. A wide variety of labels can be used. A linker can be used between the label and the protein to... Agent: Catalyst Law Group, Apc

20070122407 - Isolated nucleic acids, vectors and host cells encoding erbb3 antibodies: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein;... Agent: Genentech, Inc.

20070122406 - Optimized proteins that target ep-cam: Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.... Agent: Morgan, Lewis & Bockius, LLP

20070122410 - Use of an active substance binding to cd28 for producing a pharmaceutical composition for the treatment of b-cll: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the... Agent: Mayer & Williams PC

20070122412 - Eg-vegf nucleic acids and polypeptides and methods of use: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which... Agent: Merchant & Gould PC

20070122413 - Il-21 antagonists: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070122411 - Solid forms of anti-egfr antibodies: The invention relates to solid forms of antibodies against the EGF receptor, in particular precipitates and crystals of monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), which result in biologically active antibody protein through dissolution or suspension in aqueous medium, obtainable... Agent: Millen, White, Zelano & Branigan, P.C.

20070122414 - Surface marker-directed cancer therapeutics: Disclosed are methods for treating and/or preventing neoplasms in a patient by contacting the neoplasm with therapeutic agents capable of binding, hybridizing, or interacting with proteins on the cell surface of neoplastic cells. In addition, therapeutic compositions are disclosed for the treatment and/or prevention of a neoplasm in a patient... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070122415 - Compound and method for suppressing retroviral replication: In one aspect, the invention provides an antiretroviral peptide that suppresses replication of a retrovirus and the use thereof to inhibit retroviral replication within cells infected with a retrovirus. The method can be used in vivo to treat retroviral infection in human or veterinary subjects, and the inventive antiretroviral peptide... Agent: Leydig Voit & Mayer, Ltd

20070122416 - Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and... Agent: Stites & Harbison PLLC

20070122418 - Compositions and methods for the pulmonary delivery of aerosolized medicaments: Therapeutic dried compositions are described. The composition is in solid dose form and includes a polyol and an immunogenic agent.... Agent: Fish & Richardson P.C.

20070122417 - Immunotherapy method: The present invention relates to the use of immunomodifying agents to effect change in the T helper-type 1 (TH1) or T helper-type 2 (TH2) arms of the immune response and thereby treat TH1 or TH2 mediated diseases. In particular, the present invention relates to a method of altering a specific... Agent: Edwards Angell Palmer & Dodge LLP

20070122423 - Derp1 and proderp1 allergen derivatives: The present invention provides a novel treatment for allergy comprising the provision of a recombinant DerP1/ProDerP1 allergen derivative with hypoallergenic activity. Pharmaceutical compositions comprising said mutant allergens which stimulate a Th1-type immune response in allergic or naive individuals thereby reducing the potential for an allergic response upon contact with the... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070122421 - Innate immune system-directed vaccines: The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070122419 - Methods and compositions for treating atherosclerosis: During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (OxLDL), and active immunization of hypercholesterolemic mice with OxLDL ameliorates athero-genesis. The present studies have identified anti-OXLDL autoantibodies that share complete genetic and structural identity with antibodies produced by anti-phosphorylcholine B-cell clone, T15.... Agent: Buchanan, Ingersoll & Rooney LLP

20070122420 - Protein antigens useful for cancer therapy and vaccination: PstS1 protein or fragments thereof are highly immunogenic protein antigens for vaccination and immunotherapy of cancer in humans and animals. A wild-type or a recombinant mycobacterial PstS1 protein are used for the preparation of a vaccine or therapeutical composition for the treatment of cancer, in particular for the treatment of... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070122422 - Sodium-independent small neutral amino acid transporter transporting l- and d- amino acids: Novel sodium-independent small neutral amino acid transporters which transport L- and D-amino acids. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or 4 or an amino acid derived therefrom by deletion, substitution or addition of one or more amino acids and being capable of sodium-independently transporting... Agent: Edwards Angell Palmer & Dodge LLP

20070122424 - Peptide-based vaccine for influenza: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii)... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070122425 - Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic tags: A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070122426 - Composition containing fractionated bee propolis: A composition containing fractioned propolis wax isolated without the use of solvents. The composition contains about 24-50 mg/g of total polyphenols, about 11-18% resins, about 77-87% wax, about 2.4-5.0% polyphenols and about 0-5% other materials.... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070122427 - Delivery of trefoil peptides: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for... Agent: Howrey LLP

20070122428 - Mutant forms of cholera holotoxin as an adjuvant: Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus,... Agent: Howson And Howson

20070122432 - Compositions and methods of treating retroviral infections: The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV... Agent: Sherri L. Oslick Mcdonnell Boehnen Hulbert & Berghoff

20070122429 - Designed antigens to elicit neutralizing antibodies against sterically restricted antigen and method of using same: The invention relates to the production of sterically restricted antigens, antibodies useful for the recognition of sterically restricted antigens, and methods of identifying and/or using the same. The invention further relates to methods of using the sterically restricted antigens and antibodies to treat a disease or to prevent infection with... Agent: Trask Britt

20070122430 - Influenza vaccine compositions and methods of use thereof: Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing a protective immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure... Agent: Dla Piper US LLP

20070122431 - Reverse genetic system for rift valley fever virus and uses thereof: The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore,... Agent: Benjamin Aaron Adler Adler & Associates

20070122433 - Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability: The present invention provides a method for producing a less-painful immunogenic composition of a hydrophobic protein in a pharmaceutically acceptable carrier suitable for administering to a mammal, comprising the steps of (a) solubilizing said hydrophobic protein with a zwitterionic detergent to make a first composition; (b) altering said first composition,... Agent: Wyeth Patent Law Group

20070122434 - Heat shock genes and proteins from neisseria meningitidis, candida glabrata and aspergillus fumigatus: Methods and compositions comprising isolated nucleic acid molecules specific to Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus heat shock proteins (Hsps), as well as vector constructs and isolated polypeptides specific to the same are provided. Such compositions and methods are useful for the diagnosis of infections by these organisms and... Agent: Fish & Richardson PC

20070122435 - Topical dapsone for the treatment of acne: The present invention relates to a method of treating acne by topically applying a dermatological composition comprising dapsone. In addition to inflammatory lesions, the composition also treats non-inflammatory acne. The composition is formulated to include dapsone in a both a dissolved and microparticulate state.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070122441 - Biocidal surfaces, articles with biocidal surface agents and methods of synthesizing and evaluating biocidal surface agents: A biocidal article, includes a surface including a plurality of polymers covalently attached to the surface. The polymers include biocidal cationic groups. The polymers have a molecular weight distribution or polydispersity less than 3. A grafting density of the polymers on the surface is controlled, average degree of polymerization of... Agent: Bartony & Hare, LLP

20070122440 - Methods for producing nanoparticles: The present invention relates to methods of preparing nanoparticles from reactively formed block and/or graft copolymers and nanoparticles derived therefrom... Agent: Mueting, Raasch & Gebhardt, P.A.

20070122438 - Multifunctional self-decontaminating surface coating: e

20070122436 - Nanoparticulate active substance formulations: The invention relates to nanoparticulate formulations comprising at least one active compound or compound with a special effect and at least one random radical copolymer. The copolymers are formed from monomers carrying sulfonic acid groups and additional olefinically unsaturated compounds. The formulations are dispersible as nanoparticles in an aqueous medium.... Agent: Hutchison Law Group PLLC

20070122437 - Novel insecticide composition and use thereof particularly for impregnating mosquito nets, fly screens and the like: Materials containing at least one non-pyrethroid insecticide and at least one insect repellent, wherein the concentration of the insecticide is lower than its lethal concentration 100 (LC100) when used alone, for use as combination materials for simultaneous, separate or sequential use in the preparation of an insecticide composition.... Agent: Young & Thompson

20070122439 - Test medium, system and method for the evaluation of surfaces: The present invention provides a test medium for the evaluation of the resistance of surfaces comprising at least about 20 % by weight 3-(4-methoxyphenyl)-2-propenoic acid-2-ethylhexyl ester, at least about 20% by weight 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, at least about 20% by weight 3,3,5-trimethylcyclohexyl salicylate and at least about 20% by weight N,N-diethyl-m-toluamide. Furthermore,... Agent: General Motors Corporation Legal Staff

20070122442 - Triple-action pest control formulation and method: The present disclosure provides a triple-action pest control formulation for controlling rodents, insects, and terrestrial mollusks, the formulation including: a first active ingredient which is a rodenticide; a second active ingredient which is both an insecticide and a molluscicide; an optional attractant; and a carrier matrix. The present disclosure also... Agent: Luedeka, Neely & Graham, P.C.

20070122445 - Absorbable fatigue-enduring phosphate composites: Precursors of fatigue-enduring phosphate composites, particularly useful as self-hardening bone cement, are formed of a calcium phosphate cement grafted with trimethylene carbonate, phosphate glass, a liquid amine-bearing derivative poly(ethylene glycol-b-propylene glycol) and a liquid C-succinylated polyalkylene glycol and preferably contain at least one bioactive agent.... Agent: Leigh P. Gregory Attorney At Law

20070122443 - Amphiphilic copolymer compositions: The present invention provides an amphiphilic coating material for applying on at least a portion of one surface of an article. The amphiphilic coating material comprises a copolymer containing one or more alkyl methacrylate or alkyl acrylate co-monomer units; one or more vinyl acetate co-monomer units; and up to 40%... Agent: Philip S. Johnson Johnson & Johnson

20070122446 - Implants for treatment of symptomatic or degenerated intervertebral discs: Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of one or more active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also... Agent: Fox Rothschild, LLP

20070122444 - Medical devices employing triazine compounds and compositions thereof: The present invention relates to methods, compounds, and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses, and is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention also relates to compounds that inhibit smooth... Agent: Dr. Reddy's Laboratories, Inc.

20070122447 - Shaped bodies and methods for their production and use: Shaped, composite bodies are provided. One portion of the shaped bodies comprises an RPR-derived porous inorganic material, preferably a calcium phosphate. Another portion of the composite bodies is a different solid material, preferably metal, glass, ceramic or polymeric. The shaped bodies are especially suitable for orthopaedic and other surgical use.... Agent: Woodcock Washburn LLP

20070122449 - Biodegradable implantable drug delivery device: The invention relates to biodegradable and implantable devices for the in situ delivery of a pharmaceutical composition to a human or animal that comprise a generally discoid body, having at least one aperture through which the body is anchorable by suture, and that are formed from biodegradable polymeric compositions. The... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070122448 - Compositions and methods to create a vascularized environment for cellular transplantation: The present invention generally relates to biocompatible devices suitable for increasing cellular HIF-1 α protein levels. In particular, the present invention relates to an implant comprising a biocompatible support loaded with at least one pharmaceutical agent capable of increasing cellular HIF-1 α protein levels to promote vascularization at or near... Agent: Philip S. Johnson Johnson & Johnson

20070122450 - Treatment of ophthalmic conditions: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the... Agent: Choate, Hall & Stewart LLP

20070122451 - Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food: The present invention provides novel in vivo indigestible peptides that are highly absorbable and hardly digestible in living organism when administered orally or through other route, and expected to effectively exhibit functions, such as hypotensive effect, in living organism, and ACE inhibitors prepared with the peptides, and medicine or functional... Agent: Darby & Darby P.C.

20070122452 - Fat composition: Provided is a composition permitting high systemic absorption of n-3 polyunsaturated fatty acids and high transfer of them to tissues and capable of fully exhibiting pharmacological effects which the fatty acids have. A fat composition containing one or more phospholipids having, as a constituent fatty acid, an n-3 polyunsaturated fatty... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070122453 - Moderating the effect of endotoxins: The present invention relates to the use of an oral composition comprising meat extract and peptones, separately or in combination, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of... Agent: Bell, Boyd & Lloyd LLP

20070122457 - Nicotine and chocolate compositions: The present invention is drawn to nicotine-containing pharmaceutical compositions that comprise chocolate and method of using the compositions in different therapies, such as nicotine replacement therapy.... Agent: Fulbright & Jaworski, LLP

20070122458 - Nicotine and chocolate compositions: The present invention is drawn to nicotine-containing pharmaceutical compositions that comprise chocolate and method of using the compositions in different therapies, such as nicotine replacement therapy.... Agent: Fulbright & Jaworski, LLP

20070122456 - Nicotine and cocoa powder compositions: The present invention relates to a nicotine-containing pharmaceutical composition and methods of using the composition in therapies, such as nicotine replacement therapy.... Agent: Fulbright & Jaworski, LLP

20070122454 - Skin moisturizing agent for oral intake and functional foods and drinks: The present invention provides functional food and beverage that produce a skin moisturizing effect through oral intake, that is excellently safe, and that may be taken regularly. The invention also provides a skin moisturizer for oral intake to be used in the functional food and beverage, as well as use... Agent: Sughrue Mion, PLLC

20070122455 - Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to... Agent: Hoffmann & Baron, LLP

20070122459 - Composition and method for preventing or treating urolithiasis: A method for preventing or treating urolithiasis in an animal by feeding the animal a food composition comprising potassium in an amount equivalent to more than about 1% by weight potassium chloride and a food composition suitable for preventing or treating urolithiasis in an animal comprising potassium in an amount... Agent: Colgate-palmolive Company

20070122460 - Hot-flash wipes and clothing: Disclosed are cooling clothing and wipes to alleviate some of the symptoms of menopause, especially hot flashes and night sweats. A wipe is made of a wicking material that does not disintegrate or leave a residue as do current tissues. The wipe carries a cooling agent, such as menthol. When... Agent: Leydig Voit & Mayer, Ltd

20070122461 - Antimicrobial compositions and wound dressings: The present invention relates to a wound dressing comprising a flexible base layer and an antimicrobial material, wherein the antimicrobial material comprises an actived carbon-carried noble metal, the actived carbon is selected from the group consisting of an actived carbon powder, an actived carbon particle, an actived carbon fiber, and... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070122463 - Antimicrobial compositions and wound dressings: A wound dressing and an antimicrobial composition are provided. The wound dressing comprises a carbonaceous material, a noble metal carried on the carbonaceous material, and, optionally, a flexible base layer, wherein the carbonaceous material is selected from a group consisting of activated carbon, graphite, carbon, and a combination thereof, while... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070122462 - Bandage with a hydrophilic foam containing silver: A compression stretch bandage formed from at least one layer of a stretchable, textile material forming a body of the bandage, a base material attached to the stretchable, textile material on a first side, and a silver material attached to the base material for reducing risk of infection. The bandage... Agent: Akerman Senterfitt

20070122467 - Anaesthetic formulations: Propofol Solubilised in aqueous micellar preparations of poloxamers is stable at low concentrations and that such preparations are effective administration forms for Propofol.... Agent: Fish & Richardson PC

20070122469 - Method for producing a vesicle dispersion: A method for preparing a vesicle dispersion wherein a water-soluble substance is encupsulated in the vesicle, which comprises successively performing: a step of dispersing at least one lipid in an aqueous medium to pre-construct a vesicle dispersion, a step of drying the pre-constructed vesicles to obtain dried vesicles, a step... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070122465 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070122468 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070122466 - Sphingomyelin liposomes for the treatment of hyperactive bladder disorders: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in... Agent: The Webb Law Firm, P.C.

20070122464 - Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis: The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of... Agent: Berliner & Associates

20070122470 - New combination dosage form: The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present... Agent: White & Case LLP Patent Department

20070122473 - Aminosugar and/or glycosaminoglycan composition having therapeutic use: An embodiment of the invention provides a composition having one or more active ingredients such as an aminosugar, more particularly, glucosamine, glucosamine salt, and mixtures thereof, and a glycosaminoglycan, more particularly, chondroitin, chondroitin salts, and mixtures thereof having a therapeutic use and is stable for at least 24 months. Additionally,... Agent: Edward J. Timmer

20070122471 - Method of improving suitability for granulation: The present invention provides a granulated product having improved granulatability which contains a compound with poor wettability and a surfactant, particularly the granulated product wherein at least about 35% by weight with respect to the total weight of the product does not pass through a 100-mesh sieve, and a method... Agent: Foley And Lardner LLP Suite 500

20070122474 - Pharmaceutical preparation comprising an active dispersed on a matrix: The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix... Agent: Gary M. Nath Nath & Associates PLLC

20070122476 - Storage stable thyroxine active drug formulations and methods for their production: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070122472 - Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability: Tablets of a pharmaceutical, nutritional or vitamin active compound or composition, e.g. a poorly compressible drug are made by direct compression using a synergistic binder composition of co-processed (a) copolymer of vinylpyrrolidone (VP) and vinyl acetate (VA) and (b) microcrystalline cellulose (MCC), in a wt. ratio of (a):(b) of 1-30:99-70,... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070122475 - Taste masking composition: A composition for delivery of a medicament that has a bitter taste and/or causes throat catch is provided. The composition contains Carbomer 934, Carbomer 971, Carbomer 974, PEG-5M or a mixture thereof in an amount sufficient to mask the bitter taste of the medicament and/or throat catch.... Agent: Novartis Corporate Intellectual Property

20070122478 - Extended release composition containing tramadol: The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appears within the first hours after administration, the time to maximal Tramadol content Tmax is at least 10 hours and the peak Tramadol concentration is less... Agent: Merchant & Gould PC

20070122477 - Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency: A controlled-release pharmaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat 25-hydroxyvitamin D insufficiency or deficiency, are disclosed. The composition and method of administration preferably result in delayed release of the vitamin(s) in the ileum of the small... Agent: Marshall, Gerstein & Borun LLP

20070122479 - Threo-dops controlled release formulation: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an... Agent: Millen, White, Zelano & Branigan, P.C.

20070122481 - Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer: The invention relates to a multiparticulate modified release composition comprising a fluorocytidine derivative, preferably capecitabine, and a modified release component comprising a modified release coating, a modified release matrix material, or both. Following oral delivery, the composition in operation delivers the fluorocytidine derivative in a pulsatile manner at about six... Agent: Christian Bauer

20070122480 - Sustained release formulations: Provided is a sustained-release formulation: (a) a sustained-release core including an active ingredient and a polymer having erosion and swelling property in mammalian intestinal secretions, (b) an enteric film coating layer coated on the sustained-release core, and (c) an active ingredient-containing film coating layer coated on the enteric film coating... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070122483 - Fluocinolone acetonide drug substance polymorphic interconversion: Disclosed in embodiments herein is a method of providing the same form of FA. Regardless of which form or mixture of forms are present by forming a slurry from samples of fluocinolone acetonide containing mostly Form A and little to no Form A.... Agent: Bausch & Lomb Incorporated

20070122482 - Method for preparing modified release pharmaceutical compositions: A method for the preparation of a pharmaceutical particulate composition for modified release of one or more therapeutically, prophylactically and/or diagnostically active substances, the method involving spraying of a composition comprising an oily material on a solid composition in order to subject the solid composition to a controlled agglomeration process,... Agent: Cheryl H Agris Phd

20070122486 - Nanoparticulate insulin: Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described. The compositions exhibit retention of insulin bioactivity, increased bioavailability, and increased consistency of bioavailability as compared to prior macro-sized insulin compositions. Methods of making nanoparticulate insulin compositions, dosage forms containing them, and the... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070122485 - Organic compounds: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.... Agent: Novartis Corporate Intellectual Property

20070122484 - Parenterally administrable microparticles: A process for producing microparticles containing biologically active substance, in which process an aqueous solution of the said substance is prepared, this solution is mixed with an aqueous solution of PEG such that the substance is concentrated and/or solidified, the substance is optionally washed, the substance is mixed with an... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070122487 - (poly(acryloyl-hydroxyethyl starch)-plga composition microspheres: The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin,... Agent: Buchanan, Ingersoll & Rooney PC

20070122488 - Multi-functional microcapsules and method and device for manufacturing same: Multimicrocapsules that include encapsulated components of at least one nutritionally, pharmacologically, or medically active functional substance, wherein, within an encapsulation of one or more layers of a first encapsulating material around a common capsule matrix, there are provided a first active functional component in an amount sufficient to provide functional... Agent: Winston & Strawn LLP Patent Department

20070122489 - Putamen ovi: The present invention pertains to a method for the preparation of putamen ovi, putamen ovi having a defined grain size distribution, and to the use of putamen ovi for the treatment of calcium deficiency and other disease conditions.... Agent: Hunton & Williams LLP Intellectual Property Department

20070122490 - Wound healing compound: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprise a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide and (b) fat-soluble vitamins. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide... Agent: Keaty Professional Law Corporation Thomas S. Keaty

20070122491 - Methods and compositions for altering cell function: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g.,... Agent: Medlen & Carroll, LLP

20070122498 - Compositions for safe and effective regression of dermal vessel tortuosity: Topical compositions for Safe and Effective regression of Dermal Vessel Tortuosity in the form of ointment, cream, oil, soap and shampoo contain non aqueous herbal extract of Wrightia Tinctoria, cocos nucifera, and suitable pharmaceutically/cosmetically accepted excipients for dermal use.... Agent: Bregen Technical Consultants L.L.C.

20070122494 - Herbal composition for treatment and maintenance of hormone dependent conditions and circulatory conditions, and immunostimulation: A pharmaceutical or medicinal preparation comprising a mixture of herbs including Glycine max, Asparagus racemosa, Boerhavia diffusa, Withania somnifera, Saraca indica, and Coleus forskohlii, or a mixture of the active ingredients that have been extracted from those herbs. The herbal formulations of the present invention are effective for the treatment... Agent: Volpe And Koenig, P.C.

20070122497 - Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant: A pharmaceutical or medicinal preparation comprising a mixture of herbs including Glycine max, Coleus forskohlii, Camellia sinensis, Allium sativum, Withania somnifera, Boerhavia diffusa, and Curcuma longa, or a mixture of the active ingredients that have been extracted from those herbs. The herbal formulations of the present invention are effective for... Agent: Volpe And Koenig, P.C.

20070122496 - Herbal composition for treatment of immunocompromised conditions: According to the present invention there is provided pharmaceutical or medicinal preparation comprising a combination of two herbal compositions to be administered together. The first herbal composition comprises a mixture of the following herbs: Asparagus racemosa, Curcuma longa, Glycyrrhiza glabra, Momordica charantia, Tinospora cordifolia, Withania somnifera, Spirulina, Allium sativum, Emblica... Agent: Volpe And Koenig, P.C.

20070122495 - Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative, as well as other physiological functions: A pharmaceutical or medicinal preparation comprising a mixture of herbs including Bacopa monniera, Convolvulus pluricaulis, Nardostachys jatamansi, Valerian wallichi, Myristica fragrans, Centella asiatica, Withania somnifera, Ocimum sanctum, Acorus calamus, Boerhavia diffusa and Tinospora cordifolia or a mixture of the active ingredients that have been extracted from such herbs for treatment... Agent: Volpe And Koenig, P.C.

20070122493 - Marine algae extract and glycosidase inhibitor containing the same: A glycosidase inhibitor comprising as an active ingredient an extract of Ascophyllum nodosum which is a kind of brown algae can be used as a useful healthy food or food for specified health uses for the treatment and/or prevention of diabetes.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070122492 - Plant extracts and dermatological uses thereof: The present invention provides for plant extracts and dermatological formulations comprising one or more plant extracts that are capable of inhibiting one or more extracellular proteases selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE). The present... Agent: Heller Ehrman LLP

20070122499 - Antiseptic composition: p-Menthane-3,8-diol (PMD) has antiseptic, antibiotic, fungicidal and bactericidal properties. It is used for these purposes in the form of compositions and method comprising the PMD and optionally a carrier. A method of treating acne, folliculitis body, scalp folliculitis, Hydradinitis suppuritiva dandruff, seborrhoeic dermatitis (scalp or body), pityriasis versicolor, pityrosporun folliculitis,... Agent: Rankin, Hill, Porter & Clark, LLP

20070122500 - Cosmetic compositions in particular with anti-ageing activity comprising an extract of aframomum angustifolium or longoza plant: M

20070122501 - Formulations containing astragalus extracts and uses thereof: Formulations containing plant extracts, in particular Astragalus extracts, and their use in inducing telomerase activity in cells, are described. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in selected cells, such... Agent: Perkins Coie LLP

20070122502 - Therapeutic juice composition for women: A therapeutic juice composition is provided which is particularly advantageous and beneficial to women. This composition comprises noni fruit and a vitamin blend comprising black cohosh, a chromium composition, a calcium composition and a source of trans-resveratrol.... Agent: Karambelas & Associates

20070122503 - Use of extracts from cimicifuga racemosa and of tectorigenin as an estrogen-type, organoselective medicament having no uterotrophic effect: The present invention relates to the use of extracts from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, atherosclerosis, osteoporosis and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.... Agent: Akerman Senterfitt

20070122504 - Grape seed extract having neuronal cell-protection activity and the composition comprising the same for preventing and treating degenerative brain disease: The present invention relates to a grape seed extract showing neuronal cell protecting activity and the composition comprising the same having neuronal cell protecting activity for preventing and treating degenerative brain disease. The grape seed extract shows potent inhibiting activity of neuronal cell apoptosis occurred in brain ischemia as well... Agent: Kirk Hahn

20070122505 - Natural antioxidant additive for feed and drinking water: A natural intestine-functional additive with antioxidative properties for utilization as an additive in animal feed containing natural and/or nature identical active substances. The substance include a first active component containing antioxidative active substances derived from plant material from olive plants (Olea europaea L) and a second active component containing antioxidative... Agent: Patrick W. Rasche Armstrong Teasdale LLP

20070122507 - Histone deacetylase and tumor necrosis factor converting enzyme inhibition: The present invention relates to methods and compositions for inhibiting Histone Deacetylase (“HDAC”) and/or Tumor Necrosis Factor Converting Enzyme (“TACE”) in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of HDAC and/or TACE using processed Morinda citrifolia L. plant products.... Agent: Kirton And Mcconkie

20070122506 - Process for the isolation of oleane compounds isolated from the bark of arjun tree terminalia arjuna (roxb.): The present invention provides an improved process for the isolation of oleane compounds from the bark of Terminallia arjuna (Roxb.). More particularly, the present invention relates to an improved process for the isolation of arjunic acid and its derivates from the bark of Terminallia arjuna (Roxb.). The present invention further... Agent: Dickinson Wright PLLC

20070122509 - Antioxidant dietary supplement compositions and methods for maintaining healthy skin: Compositions and methods for maintaining healthy skin and alleviating skin conditions such as redness, inflammation, irritation and skin aging, as well as for maintaining healthy scalp and hair are disclosed. The oral compositions disclosed comprise antioxidants including lycopene, gallic acid and ascorbic acid. Preferably lycopene containing tomato compositions has been... Agent: Frost Brown Todd, LLC

20070122508 - Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease: The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070116644 - Cobalamin conjugates useful as imaging and therapeutic agents: The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis.... Agent: Fish & Richardson P.C.

20070116645 - Methods and compositions for inhibiting cholesterol uptake: The present invention is directed to a method for the lowering of levels of LDL cholesterol in an individual comprising administering to the individual an agent which modulates the activity of the protein annexin 2, cyclophilin A, cyclophilin 40, or HSP 56 or the complex of annexin 2 and caveolin... Agent: David S Rastrick Nixon Peabody

20070116648 - Optimized relaxivity and specificity hepatobiliary mri contrast agent: An adamantane functionalized magnetic resonance imaging (MRI) contrast agent has been synthesized, and shows high liver specificity, prolonged retention time in both the liver and kidneys, the highest relaxivity among clinical contrast agents, high water solubility, thermodynamic stability, signal intensity enhancement, hepatocellular uptake, and low osmolality and toxicity.... Agent: Cooper & Dunham, LLP

20070116647 - Medicinal preparation particularly for the treatment of slipped discs hernias: The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070116646 - Optical imaging of endometriosis: The invention provides contrast agents for optical imaging of endometriosis in patients. The contrast agent may be used in diagnosis of endometriosis, for follow-up of progress in disease development, and for follow-up of treatment of endometriosis. Further, the invention provides methods for optical imaging of endometriosis. The contrast agent has... Agent: Ge Healthcare, Inc.

20070116649 - Antibiotic formulations, unit doses, kits, and methods: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the... Agent: Nektar Therapeutics

20070116650 - Device, method and use for the formation of small particles: The invention relates to a device for producing small particles of a certain substance. The device includes first inlet means (4) for a solution or a suspension containing the substance and second inlet means (3) for an atomizing agent. The device further includes mixing means (12) for the solution and... Agent: Cantor Colburn, LLP

20070116651 - Recombinant protein comprising starch binding domain and use thereof: A recombinant protein is prepared comprising a polypeptide of interest and a starch binding domain (SBD). The said SBD is obtainable from glucoamylase of fungi genus Rhizopus. The said recombinant protein comprising the said SBD can be purified by contacting with an affinity matrix such as starch, the SBD binds... Agent: Harness, Dickey & Pierce, P.L.C

20070116652 - Red herbal dentifrice: A dentifrice composition of the invention can be applied to teeth and/or gums by any conventional A dentifrice composition comprises (a) calcium carbonate having properties of particle size and angularity effective to provide mild abrasivity to dental enamel; (b) red iron oxide of low abrasivity in an effective amount on... Agent: Colgate-palmolive Company

20070116654 - Cosmetics: The cosmetic of the present invention is a cosmetic that alleviates skin irritation by blending in polypropylene glycol, a specific polar oil, or polybutylene glycol, as well as an ultraviolet absorbent. The present invention also relates to an agent and a method for alleviating irritation by lipophilic drugs. Since the... Agent: Townsend & Banta C/o Portfolio Ip

20070116653 - Hair treatment compositions: The present invention relates to hair treatment compositions and methods. More particularly, the invention relates to hair treatment compositions comprising lipids and creatine. The hair treatment compositions of the present invention may be used to improve the tensile properties of hair, such as hair elasticity and strength.... Agent: Bryan Cave LLP

20070116655 - Malodor counteractant compounds: e

20070116656 - Optically appealing cosmetic or dermatological preparation: A cosmetic or dermatological preparation which comprises an aluminum containing antiperspirant active ingredient, an α-hydroxycarboxylic acid, water and optionally, a plurality of particles in a stably suspended state. This Abstract is not intend